CaSRevolution Raises 1.3 Million on CrowdFundMe to Develop Treatment for Alzheimer’s

CaSRevolution, which aims to patent molecules against Alzheimer’s by exploiting an innovative mechanism of action, has closed its equity crowdfunding campaign on the CrowdFundMe platform , exceeding the minimum target of 1.2 million euros and raising over 1.3 million , based on a pre-money valuation of 6 million.

If you want to read more about CaSRevolution and to find the most important business news of the day, download for free our companion app Born2Invest.

CaSRevolution equity crowdfunding round

Among the 71 investors, Utopia SIS, an investment company specializing in healthcare and biomedical, promoted and participated by the Golinelli Foundation, the Sardinia Foundation and the executive vice president Antonio Falcone, also participated in the campaign with an investment of 800 thousand euros.

Also considering the 2023 round, CaSRevolution has raised more than €2 million. The company features an excellent team, including Luca Benatti, founder of Newron (listed on the Swiss Stock Exchange) and ex-CEO of Erydel (which raised more than €50 million from VC funds and was recently acquired by Quince Therapeutics) , as well as member of the Advisory Board of the Sofinnova Telethon fund.

Research and development for Alzheimer’s

CaSRevolution is developing a treatment for Alzheimer’s disease by exploiting an innovative approach with the aim of stopping or at least slowing down neurodegeneration, exploiting a new receptor-based mechanism of action, which explains the clinical manifestations of the pathology.

To date, there are no effective treatments on the market, which is why the broadcaster is focusing on an innovative approach that has the ambition of creating not a mere palliative, but a highly effective therapy.

Among the activities successfully carried out, CaSRevolution carried out a virtual screening on millions of molecules in collaboration with the University of Padua and the synthesis of new molecules together with the University of Salerno.

The blood-brain barrier passage test was also validated, and the preparation of the secondary assay on cellular models began, as well as the collaboration with Columbia University for the analysis of post-mortem brain tissues of patients suffering from Alzheimer’s disease. Alzheimer’s

Benatti firmly believes in CaSRevolution: “ The team is extremely experienced, having already created companies, raised capital from funds, developed drugs for the treatment of neurodegenerative diseases and brought new therapeutic approaches to the market. The science behind the initiative is solid and strengthened by independent validations .”

Furthermore, Benatti underlined that ” neurodegenerative diseases represent an unmet need, with a consequent interest from Big Pharma who are looking for new molecules for their pipelines, thus offering very interesting exit opportunities for CaSRevolution. Also for these reasons I decided to participate directly as an investor in the company, together with Italian Angels for Biotech, and to join the Board of Directors with executives with very long experience, such as Andrea Pellacani, now Head of R&D of Alfasigma.”

__

(Featured image by StevenHWG via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Crowdfunding buzz. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us